A meta-analysis also found that glycolysis-enhancing drugs, such as PGK1 activators, were associated with a lower incidence of PD, further supporting the neuroprotective potential of these pathways (Ribeiro et al., 2024). The gene discussed is PGK1; the disease is Parkinson disease.